Health Catalyst Income Statement 2025-2011 | HCAT

Brief overview of revenue and earnings at Health Catalyst

The comparison covers a five-year financial horizon. The revenue attributed to Health Catalyst moved from 189 million dollars to 311 million dollars between the two endpoints. The cumulative result was +64.8%, corresponding to roughly 10.5% per year. Top-line growth remained consistently strong over the period.

The five-year change in gross profit reached +67.1%: from 90.8 million dollars to 152 million dollars. Direct costs broadly followed the top-line trend. The gross margin was 48.1% at the start and 48.7% at the end. The relationship between gross profit and revenue changed only slightly.

The operating result measured by EBITDA moved from −77.4 million dollars to −110 million dollars, or −42.6%. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −41% to −35.5%. The company improved its ability to convert sales into EBITDA.

The final result was −$115 million initially and −$178 million in the final year. The negative result deepened, showing weaker final efficiency.

The market value of the business moved from 1.7 billion dollars to 125 million dollars, or −92.7%. The decline in value indicates softer investor confidence.

What the figures show

The financial trajectory is weak and requires a cautious interpretation. The strongest signals are steady gross profitability, higher operating efficiency and a larger revenue base. Caution is warranted because of lower net income, lower investor confidence and a low EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.